Solid organ transplantation coupled with a hematopoietic stem cell transplant from the organ donor allows for the recipient to cease immunosuppressive therapy after transplant via a chimeric immune system. This beneficial effect of stem cell transplants is negatively affected by graft versus host disease (GVHD). Better understanding of the donor and recipient's immune system is vital to mitigating graft versus host disease and induction of donor chimerism without GVHD. In this study, flow cytometry was used to characterize immune cells of the recipients' before and up to eighteen months post transplantation. The recipients were categorized into their respective chimeric groups.
Fully durable chimeric subjects did not reconstitute naïve T cells to pre-transplant levels by eighteen months post-transplant whereas the transiently chimeric subjects reconstituted. The goal was to find an immune cell biomarker for chimerism but due to the limited number of transiently chimeric subjects, the data showed no significant difference. [3] . This poses negative side effects which include a reduced immune system and an increased risk of developing cancer and opportunistic infections [4] . However, with the HSC transplant, the recipient will still take immunosuppressive drugs for a short period of time and then cease treatment to allow time for the donor and recipient cells to form a chimeric immune system where both the recipient and donor cells are active and cooperative [5] .
vi
Due to the toxicity of immunosuppressive therapies [6] is performed at day -1. On day 0, the kidney transplant is performed and the FCRx infusion is performed day +1. Another treatment of Cy is administered at day +3. At this point, the recipient's immune system is reduced to very low levels of white blood cells (WBC). Engraftment of donor cells and recovery of recipient cells is monitored and determined at certain time points post-transplant. MMF is ceased at 6 months posttransplant and tacrolimus at 12 months if a stable level of donor chimerism is determined [5] . A timeline of conditioning and events is presented in Figure 1 .
Massachusetts General Hospital (MGH) and Stanford are also working with a combined HSC and organ transplant model to achieve chimerism. The MGH group concentrates on tolerance via achieving transiently mixed chimerism [11] . Stanford achieved a persistent mixed chimerism in combined transplant subjects that were human leukocyte antigen (HLA) matched donor and recipient but zero chimerism in HLA mismatched transplants [11] . 
Hypothesis:
Characterizing the immune cell populations of the recipient pre-and posttransplantation is important to determine if varying levels of chimerism result in differences in the repopulation of immune cell subsets. Regulatory T cells are involved in downregulating the immune system [12] and may be involved in aiding induction of chimerism long term. The hypothesis was that we would find a divergence of at least one immune cell type between the two chimeric groups, fully durable and transiently chimeric, that would be a novel biomarker for chimerism. 
Sample Staining:
Third party, healthy human donor whole blood was used for unstained and single color compensation controls to properly set the parameters on the flow cytometer and followed staining steps for tubes that did not have intracellular markers added.
Samples were stained in Fisher flow tubes using 20µl of BD extracellular antibodies that were previously titrated on third party, healthy human donor whole blood for optimal staining. Upon antibody staining, the cells were incubated at 4°C for 30 minutes. After incubation, the cells were gently ratcheted to break up any pellets that 
Flow Cytometry:
The prepared controls and subject samples were acquired on a BD LSRII flow cytometer with a threshold set to eliminate any remaining red blood cells still present in any of the tubes. The flow cytometer rate was set at medium to reduce the possibility of doublets occurring in the flow cell. Forward Scatter (FSC) and Side Scatter (SSC) were adjusted on the unstained subject sample tube after compensation was set. Each tube was acquired until 100,000 total events were recorded.
Samples were analyzed using BD FACSDiva software. The number of CD4 + regulatory T cells was recorded along with the total number of events. The absolute cell number was calculated by multiplying the WBC number by the percent of the cell population of interest.
Statistical Analysis:
Subjects were grouped into their respective chimerism groups and the average among the chimeric group was determined for each time point. Standard error of the mean was calculated and used for generating error bars in the graphs. A two-tailed Student's t-test with unequal variance was performed to compare the fully durable to the transiently chimeric groups at each time point. This was because the two chimeric groups are unequal in the number of subjects in their respective groups. A p-value of 0.05 or lower is considered significant for the data presented.
RESULTS
Clinical subjects were sorted into sets of chimeric groups. Fully durable chimerism includes subjects that developed a homeostatic chimeric immune system between the recipient and the donor. These subjects were weaned off of immunosuppressive therapies by twelve months post kidney transplantation. Transiently chimeric subjects started showing decreased levels of chimerism between months one and three post combined kidney/FCRx transplant, but showed zero percent chimerism in their whole blood by twelve months post transplantation. These subjects have to continue immunosuppressive therapies. One subject never obtained a level of chimerism above zero percent. In total, there are eight subjects that are fully chimeric, four that are transient, and one that never became chimeric and the chimeric groups are listed in Table   1 .
Lineage reconstitution of FCRx recipients was monitored and assessed. Due to the conditioning, the absolute cell number of CD3 + cells showed a decrease posttransplantation. B cells and NK cells recovered faster than T cells and, by six months post-transplant, were larger in number than pre-transplant levels in both chimeric groups and are shown in Figures 2 and 3 [5] . Interestingly, the transiently chimeric subjects' NK cells exceeded the pre-transplant absolute cell number by eighteen months posttransplantation. Since the transiently chimeric subjects are no longer tolerant, their NK cells could be mounting a response to the foreign graft including donor cells [13] . . Naïve CD4 + subpopulations, however, did not return to pre-transplant levels and is reflected in both fully durable and transiently chimeric groups [5] . The naïve CD8 + cells did not return to pre-transplant levels for the fully durable group but did return to a similar state for the transiently chimeric subjects by nine months posttransplant.
Regulatory T cells were defined as CD4 + /CD25 + /FoxP3 + and our gating strategy is listed in Figure 7 . Comparing the fully durable to the transiently chimeric groups, I
found there to be no significant difference pre combined kidney/FCRx transplant, which was to be expected. Three months post-transplant, data showed that both chimeric groups had drastically reduced levels of regulatory T cells due to the subjects' irradiation and immunosuppressive therapies. Considering Figure 8 , once MMF was discontinued, a divergence of the regulatory T cells was observed between fully durable and transiently chimeric subjects, which became more prominent at twelve months, when tacrolimus was discontinued, and even more at eighteen months post-transplantation, though there was no significant difference. The transiently chimeric subjects' regulatory T cells never completely recovered to pre-transplant levels and remained similar to their three month post-transplant levels. did not return to pre-transplant levels. This data was previously published in [5] . . This impact is of vital consequence because rejection has previously been linked to the survival of the sold organ transplant [16] .
The scope of this thesis' work was to characterize the immune cells in these subjects and potentially find a trend of divergence between the fully durable and the transiently chimeric subjects. While most cell types showed no significant difference between the two groups, the post-transplant CD8 + naïve T cells and CD4 + regulatory T cells, that were measured, alluded to a pattern of divergence from pre-transplant levels.
Despondently, because the transiently chimeric group had only four subjects, the range of data for the aforementioned cell types is extensive and no significant difference between the chimeric groups was able to be ascertained.
Future Experiments:
Due to the transiently chimeric group only having four subjects, it would be of scientific benefit to have a greater number of subjects that lost chimerism after transplant and before immunosuppressive therapy was ceased. While this is not ideal for subjects and the ultimate goal of the combined kidney + FCRx transplant model is to induce chimerism, a greater understanding of the aberration of the CD8 + naïve T cells and the CD4 + regulatory T cells of transiently chimeric subjects versus fully durable subjects may lead to the discovery of a predictive biomarker for chimerism.
There are other immune biomarkers that may possibly predict chimerism in subjects that received a combined transplantation. Dysregulation of miRNA levels in urine analysis has been observed in diseased conditions of kidney transplants [17] [18].
Elevated levels of the exosome neutrophil gelatinase-associated lipocalin (NGAL), have been shown to be early predictors of delayed transplant function [19] . Early detection of transplant rejection can be assessed by detecting low levels of PARP1 in the recipient's serum [20] . These potential biomarkers are minimally invasive, may detect transplant rejection at an early onset, and should be explored further.
SUMMARY AND CONCLUSION
The characterization of select immune cells in subjects enrolled in the combined kidney + FCRx study has shown that naïve CD4 
